1. Scrip
  2. >>Business

INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve

 
• By Mandy Jackson

Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.

Bishop Hans, Juno
Juno Therapeutics Inc. President and CEO Hans Bishop • Source: Juno Therapeutics Inc.

Immuno-oncology drug developers are generating a flood of new information about how to safely boost the immune system's ability to fight cancer and Juno Therapeutics Inc. is standing in front of the firehose trying to make sense of the data.

Juno's President and CEO Hans Bishop said in an interview with Scrip that one of the company's goals is to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.